Analyst Rating Update on Wright Medical Group (WMGI)

Wright Medical Group (WMGI) : The consensus on Wright Medical Group (WMGI) based on 19 analyst recommendation on the company stock is 1.32, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 15 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Wright Medical Group (WMGI) : Average target price received by Wright Medical Group (WMGI) is $26.31 with an expected standard deviation of $3.97. The most aggressive target on the stock is $33, whereas the most downbeat target is $22. 13 financial analysts are currently covering the stock.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the JP Morgan upgrades the rating on Wright Medical Group (NASDAQ:WMGI). The brokerage firm has issued a Overweight rating on the shares. The shares were previously rated Neutral. The Analysts at the ratings agency raises the price target from $21 per share to $26 per share. The rating by the firm was issued on July 13, 2016.


Wright Medical Group (NASDAQ:WMGI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $22.60 and $22.60 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $25.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.77, notching a gain of 12.23% for the day. The total traded volume was 5,379,006 . The stock had closed at $21.18 on the previous day.

Wright Medical Group, Inc. is a global specialty orthopaedic company. The Company through Wright Medical Technology, Inc. (WMT) and other subsidiaries provides extremity and biologic solutions that enable clinicians to alleviate pain and restore the patients lifestyles. The Company operates through three segments: U.S., International and BioMimetic. The Companys business includes products that are used in foot and ankle repair, upper extremity products and biologics products, which are used to replace damaged or diseased bone, to stimulate bone growth and to provide other biological solutions for surgeons and patients. The Companys products include extremity hardware, foot and ankle hardware, upper extremity hardware and biologics.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.